161 related articles for article (PubMed ID: 24671680)
41. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
Sinkovics JG; Horvath JC
Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
[TBL] [Abstract][Full Text] [Related]
42. [Development of conditionally replicating oncolytic HSV vector--targeted gene therapy for sarcoma by oncolytic viruses].
Takahashi K; Yamamura H
Nihon Rinsho; 2006 Mar; 64 Suppl 3():326-33. PubMed ID: 16615493
[No Abstract] [Full Text] [Related]
43. Allele replacement: an application that permits rapid manipulation of herpes simplex virus type 1 genomes.
Horsburgh BC; Hubinette MM; Qiang D; MacDonald ML; Tufaro F
Gene Ther; 1999 May; 6(5):922-30. PubMed ID: 10505118
[TBL] [Abstract][Full Text] [Related]
44. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
45. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
Fu X; Tao L; Zhang X
Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
[TBL] [Abstract][Full Text] [Related]
46. Naturally oncolytic viruses.
Roberts MS; Lorence RM; Groene WS; Bamat MK
Curr Opin Mol Ther; 2006 Aug; 8(4):314-21. PubMed ID: 16955694
[TBL] [Abstract][Full Text] [Related]
47. Intravesical treatment of advanced urothelial bladder cancers with oncolytic HSV-1 co-regulated by differentially expressed microRNAs.
Zhang KX; Matsui Y; Lee C; Osamu O; Skinner L; Wang J; So A; Rennie PS; Jia WW
Gene Ther; 2016 May; 23(5):460-8. PubMed ID: 26905370
[TBL] [Abstract][Full Text] [Related]
48. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
49. Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy.
Kasuya H; Nishiyama Y; Nomoto S; Goshima F; Takeda S; Watanabe I; Nomura N; Shikano T; Fujii T; Kanazumi N; Nakao A
Cancer Gene Ther; 2007 Jun; 14(6):533-42. PubMed ID: 17415379
[TBL] [Abstract][Full Text] [Related]
50. Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice.
Walker JD; Sehgal I; Kousoulas KG
J Virol; 2011 Jul; 85(14):7363-71. PubMed ID: 21543507
[TBL] [Abstract][Full Text] [Related]
51. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10.
Zhang L; Daikoku T; Ohtake K; Ohtsuka J; Nawa A; Kudoh A; Iwahori S; Isomura H; Nishiyama Y; Tsurumi T
J Virol Methods; 2006 Nov; 137(2):177-83. PubMed ID: 16854473
[TBL] [Abstract][Full Text] [Related]
52. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome.
Saeki Y; Fraefel C; Ichikawa T; Breakefield XO; Chiocca EA
Mol Ther; 2001 Apr; 3(4):591-601. PubMed ID: 11319922
[TBL] [Abstract][Full Text] [Related]
53. The molecular basis of herpesviruses as oncolytic agents.
Menotti L; Campadelli-Fiume G; Nanni P; Lollini PL; De Giovanni C
Curr Pharm Biotechnol; 2012 Jul; 13(9):1795-803. PubMed ID: 21740356
[TBL] [Abstract][Full Text] [Related]
54. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.
Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R
Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068
[TBL] [Abstract][Full Text] [Related]
55. Turning killer into cure -- the story of oncolytic herpes simplex viruses.
Zhang SX
Discov Med; 2015 Nov; 20(111):303-9. PubMed ID: 26645902
[TBL] [Abstract][Full Text] [Related]
56. The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles.
Tang G; Wang D; Zhao X; Feng Z; Chen Q; Shen Y
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835091
[TBL] [Abstract][Full Text] [Related]
57. Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures.
Passer BJ; Wu CL; Wu S; Rabkin SD; Martuza RL
Gene Ther; 2009 Dec; 16(12):1477-82. PubMed ID: 19693098
[TBL] [Abstract][Full Text] [Related]
58. Oncolytic vaccinia virus: from bedside to benchtop and back.
Thorne SH
Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
[TBL] [Abstract][Full Text] [Related]
59. Next-generation oncolytic vaccinia vectors.
Thorne SH
Methods Mol Biol; 2012; 797():205-15. PubMed ID: 21948478
[TBL] [Abstract][Full Text] [Related]
60. Herpes simplex virus type 1-derived recombinant and amplicon vectors.
Fraefel C; Marconi P; Epstein AL
Methods Mol Biol; 2011; 737():303-43. PubMed ID: 21590403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
